Total
0
Shares
Cellmid (ASX:CDY) midkine patents granted in the U.S. and Europe
  • Cellmid (CDY) has received notice of allowance for an improved antibody patent from the United States Patent and Trademark Office
  • Key U.S. and European patents have now been granted for its midkine antibodies
  • These patents secure protection for midkine antibodies to treat cancer, inflammatory diseases and auto-immune disorders
  • Cellmid is currently up a steady 7.14 per cent with shares trading for 22.5 cents apiece

Cellmid (CDY) has received notice of allowance for the improved antibody patent from the United States Patent and Trademark Office (USPTO).

Additionally, following a Notification of Intention to Grant from the European Patent Office (EPO) for the Improved midkine antibody patent, the EPO has now issued a decision to grant.

The simultaneous granting of these patents in the U.S. and key European areas represents a major milestone in the midkine therapeutic program.

The humanised therapeutic antibody covered by both the patents is one of the lead drugs in the midkine program and adds significant commercial value to the comprehensive intellectual property portfolio around midkine.

This newly granted midkine antibody patents and allied patent families underpin Cellmid's dominant intellectual property position over the use of midkine therapeutic antibodies for the treatment of diseases arising from cancer and chronic inflammation.

Midkine is a growth factor that is highly expressed during embryonic development and it modulates many important biological interactions such as cell growth, cell migration and cellular adherence.

These functions are relevant to cancer, inflammation, autoimmunity, wound healing, and. nerve growth and repair.

Midkine is barely detectable in healthy adults and only occurs as a consequence of the pathogenesis of a number of disorders.

It's often evident very early in disease onset even before any apparent physical symptoms and it's only evident in a disease context and targeting midkine is not expected to harm normal healthy tissues.

Cellmid's total midkine patent portfolio currently comprises of 67 patents and applications in 12 patent families.

Cellmid is currently up a steady 7.14 per cent with shares trading for 22.5 cents apiece at 11:40 am AEDT.


Subscribe


CDY by the numbers
More From The Market Herald
Admedus (ASX:AHZ) to begin first in-human aortic valve replacement trial

" Admedus (ASX:AHZ) to begin first in-human aortic valve replacement trial

Admedus (AHZ) has received approval for the first in-human surgical aortic valve replacement (SAVR) trial of its ADAPT single-piece 3D aortic valve.
ImpediMed (ASX:IPD) reports increased revenue for December quarter

" ImpediMed (ASX:IPD) reports increased revenue for December quarter

Medical software technology company ImpediMed (IPD) has reported increased revenue for the December 2019 quarter.
MyFiziq (ASX:MYQ) races to partner with U.S. fitness brand

" MyFiziq (ASX:MYQ) races to partner with U.S. fitness brand

MyFiziq (MYQ) has signed a binding term sheet with Bearn, the owner and operator of an “earn while you burn” fitness app.
Creso Pharma (ASX:CPH)  reaches 3 million sale milestone for Anibidiol

" Creso Pharma (ASX:CPH) reaches 3 million sale milestone for Anibidiol

Creso Pharma (CPH) has now sold over three million Anibidiol granule sachets since the products launch in 2017.